Abstract
The progressive memory loss observed in Alzheimers disease (AD) is accompanied by an increase in the levels of amyloid-β peptide (Aβ) and a block of synaptic plasticity. Both synaptic plasticity and memory require changes in the expression of synaptic proteins such as the activity-regulated cytoskeleton-associated protein, Arc (also termed Arg3.1). Using a model of synaptic plasticity in which BDNF increases Arc expression in cultured cortical neurons, we have found that an oligomeric form of Aβ strongly inhibits the BDNF-induced increase of Arc expression. Given that Aβ oligomers are likely to be involved in the synaptic dysfunction and cognitive impairment observed in amyloid depositing mouse models, we hypothesize that inhibition of Arc induction by BDNF contributes to the synaptic and memory deficits at early stages of AD.
Keywords: Synaptic plasticity, Arg3.1, Arc, Alzheimer's disease, LTP, BDNE
Current Alzheimer Research
Title: Oligomers of β-Amyloid Peptide Inhibit BDNF-Induced Arc Expression in Cultured Cortical Neurons
Volume: 4 Issue: 5
Author(s): Valentine Echeverria, Diego E. Berman and Ottavio Arancio
Affiliation:
Keywords: Synaptic plasticity, Arg3.1, Arc, Alzheimer's disease, LTP, BDNE
Abstract: The progressive memory loss observed in Alzheimers disease (AD) is accompanied by an increase in the levels of amyloid-β peptide (Aβ) and a block of synaptic plasticity. Both synaptic plasticity and memory require changes in the expression of synaptic proteins such as the activity-regulated cytoskeleton-associated protein, Arc (also termed Arg3.1). Using a model of synaptic plasticity in which BDNF increases Arc expression in cultured cortical neurons, we have found that an oligomeric form of Aβ strongly inhibits the BDNF-induced increase of Arc expression. Given that Aβ oligomers are likely to be involved in the synaptic dysfunction and cognitive impairment observed in amyloid depositing mouse models, we hypothesize that inhibition of Arc induction by BDNF contributes to the synaptic and memory deficits at early stages of AD.
Export Options
About this article
Cite this article as:
Echeverria Valentine, Berman E. Diego and Arancio Ottavio, Oligomers of β-Amyloid Peptide Inhibit BDNF-Induced Arc Expression in Cultured Cortical Neurons, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018190
DOI https://dx.doi.org/10.2174/156720507783018190 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Botulinum Toxin as a Neuro-Relearning Drug Tool in Motor Paralytic Disorders
Current Drug Therapy Traversing the Skin Barrier with Nano-emulsions
Current Drug Delivery 23Na Magnetic Resonance Imaging for the Determination of Myocardial Viability: The Status and the Challenges
Current Vascular Pharmacology Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Current Drug Targets Epigenetic Mechanisms in Alzheimer's Disease
Current Medicinal Chemistry A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Optical Sensors for Detection of Amino Acids
Current Medicinal Chemistry Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment
Current Alzheimer Research Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design Gliomas: Current Issues in Diagnosis and Treatment
Current Medical Imaging P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Metabolic Fate of Endocannabinoids
Current Neuropharmacology Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Clozapine Safety, 40 Years Later
Current Drug Safety The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology